Isolation and Application of a Llama-derived Single Domain Antibody Binding to Glycoprotein D of HSV-2
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
herpes simplex virus-2 (HSV-2) infection
Modality
Monoclonal Antibody
Mechanism
antibody-toxin fusion
Target
Glycoprotein D (HSV-2 gD)
rNPV Envelope
Low
-$44.5M
costs +25% · peak −25%
Base
-$32.0M
cumulative PoS 3.2%
High
-$19.5M
costs −25% · peak +25%
Costs follow a biologic/immunotoxin profile but are below oncology ADC levels because the likely initial HSV indication would be a focused infectious-disease population. PoS is below mainstream antiviral development because the asset is a VHH-toxin fusion with delivery and local-toxicity questions, and because generic oral antivirals set a severe efficacy/pricing bar.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.70
Modality fit · 30%
0.51
Whitespace · 30%
0.50
Composite 0.584 — composite-score rank #31 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#21) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Pritelivir (AiCuris) - HSV helicase-primase inhibitor
Most relevant active HSV therapeutic benchmark. It is not an antibody, but it shows the bar for a new HSV drug: oral antiviral efficacy in refractory immunocompromised patients, not a broad cure claim.
Criteria 2 and 3: same infection and advanced clinical pathway; different modality and therefore a commercial/regulatory anchor, not a mechanism match.
HDIT101 - anti-HSV glycoprotein B monoclonal antibody
Closest clinical antibody-class precedent for HSV. It validates that HSV envelope antibodies can reach humans but also shows a high bar versus cheap episodic/suppressive valacyclovir.
Criteria 2 and 4: same virus and antibody modality, but gB rather than gD and no toxin payload.
Acyclovir / valacyclovir / famciclovir generic antivirals
Standard-of-care commercial anchor. Generic nucleoside antivirals are cheap, safe, and guideline-supported, so any HSV-2 immunotoxin must focus on refractory, localized, or special-population use rather than routine suppression.
Criteria 2: same disease and real-world standard of care; anchors market ceiling and pricing pressure.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $14.0M | 24 mo | 42.0% | [0] [3] |
| Phase I | $42.0M | 18 mo | 60.0% | [2] [3] |
| Phase II | $85.0M | 30 mo | 30.0% | [1] [2] [3] |
| Phase III | $170.0M | 36 mo | 50.0% | [1] [2] |
| NDA/BLA Review | $12.0M | 12 mo | 85.0% | [1] [2] |
Multiplier handling: Eligible multipliers (serious_refractory_population) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$250.0M peak · WACC 14.0%
Peak revenue. HSV-2 prevalence is high, but the routine market is dominated by inexpensive acyclovir/valacyclovir/famciclovir. A VHH-toxin fusion is modeled only for refractory, recurrent, or localized high-need use where a biologic can justify pricing; the illustrative $250M peak deliberately avoids treating HSV-2 prevalence as an addressable biologic market.
WACC. The antiviral market has clear endpoints, but the antibody-toxin format, genital/local delivery questions, and generic competition keep risk high.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$32.0M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$122.6M
P25
-$51.1M
P50 (median)
-$17.0M
P75
-$9.3M
P95
-$4.1M
Prob ≥ 0
3.0%
Evidence register
5 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is a VHH antibody-toxin fusion targeting HSV-2 gD cmo_findings.asset_class_reality | Isolation and Application of a Llama-derived Single Domain Antibody Binding to Glycoprotein D of HSV-2 regulatory | 2014-01-01 | high |
Generic antivirals are standard of care peak_revenue_usd | CDC Herpes STI Treatment Guidelines regulatory | 2021-07-22 | high |
Pritelivir active clinical benchmark comparators[0] | AiCuris pritelivir Phase 3 primary endpoint announcement news | 2025-10-16 | high |
HDIT101 HSV antibody precedent comparators[1] | EU trial results for HDIT101 versus valaciclovir trial_disclosure | 2022-01-01 | medium |
HSV antibody field context stage_profile.phase_2.pos | Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus peer_review | 2024-04-30 | medium |
Thesis
Why this asset earns its rank
This is a real therapeutic concept, but it is not a conventional mAb: it is a llama-derived VHH single-domain antibody fused to a toxin and directed against HSV-2 glycoprotein D. That makes the pinned monoclonal_antibody bucket an approximation. The CMO question is less whether gD is extracellular and drug-accessible - it is - and more whether an immunotoxin can be delivered safely to infected tissue and justify biologic pricing in a disease managed with cheap oral antivirals.
Comparator economics are unforgiving. Pritelivir is the active late-stage HSV benchmark in refractory immunocompromised patients; HDIT101 is the closest HSV antibody precedent; and acyclovir/valacyclovir/famciclovir remain the real commercial standard. The engine result is -$44.5M to -$19.5M, with a base rNPV of -$32.0M and cumulative PoS of 3.2%; that supports a partnership_candidate archetype only if the program targets refractory or special-population HSV rather than routine suppressive treatment.
Verdict: scientifically plausible but commercially narrow. It earns its rank because HSV-2 has large prevalence and the gD target is accessible, but a fundable path requires a niche where a toxin-fusion biologic is safer, faster, or meaningfully better than generics and pritelivir.
Key risks
Asset-specific, not generic biotech risks
- Modality mismatch: this is a VHH-toxin immunotoxin, not a plain antibody; safety and local tissue injury are central risks.
- Commercial compression: generic acyclovir/valacyclovir/famciclovir make broad HSV-2 biologic pricing unrealistic.
- Competitive timing: pritelivir has Phase 3-positive refractory-HSV data and could define the high-need niche before a VHH-toxin reaches clinic.
- Delivery risk: genital mucosal or neuronal-reservoir HSV biology may not be amenable to toxin delivery without unacceptable off-target effects.